Syndax Pharmaceuticals, Inc. - Common Stock (NQ:SNDX)

20.16 -0.36 (-1.75%)

Streaming Delayed Price Updated: 2:05 PM EST, Jan 20, 2026 Add to My Watchlist

Price and Volume

Volume	575,794
Open	20.10
Bid (Size)	20.13 (200)
Ask (Size)	20.17 (200)
Prev. Close	20.52
Today's Range	19.71 - 20.71
52wk Range	8.580 - 22.73
Shares Outstanding	69,484,053
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Syndax Reports Preliminary 2025 Financial Highlights and Provides Business Updates at the 44th Annual J.P. Morgan Healthcare Conference

January 12, 2026

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.

January 07, 2026

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Performance

YTD	-5.4%	-5.4%
1 Month	-6.1%	-6.1%
3 Month	+29.5%	+29.5%
6 Month	+107.2%	+107.2%
1 Year	+47.5%	+47.5%

More News

Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

January 05, 2026

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Earnings Scheduled For November 3, 2025 ↗

November 03, 2025

Via Benzinga

Syndax Pharmaceuticals's Earnings Outlook ↗

October 31, 2025

Via Benzinga

SNDX Stock Is The Talk Of The Town Today: Here’s Everything To Know About The Latest FDA Approval ↗

October 24, 2025

Via Stocktwits

The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally

December 22, 2025

Via MarketMinute

Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025

December 12, 2025

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum

December 08, 2025

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

December 03, 2025

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference

December 01, 2025

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

November 05, 2025

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

November 03, 2025

Via Benzinga

Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update

November 03, 2025

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025

November 03, 2025

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025

November 03, 2025

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax Announces Participation in November Investor Conferences

October 30, 2025

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025

October 27, 2025

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Why Is Syndax Stock Down Today? ↗

October 24, 2025

Via Benzinga

Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

October 24, 2025

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Where Syndax Pharmaceuticals Stands With Analysts ↗

October 16, 2025

Via Benzinga

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

October 03, 2025

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

September 19, 2025

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

September 05, 2025

From Syndax Pharmaceuticals, Inc.

Via GlobeNewswire

Syndax Gains Attention With Strong Drug Portfolio, Path To Leukemia Market Growth ↗

September 04, 2025

Via Benzinga

Frequently Asked Questions

Is Syndax Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Syndax Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Syndax Pharmaceuticals, Inc. - Common Stock trade on?

Syndax Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Syndax Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Syndax Pharmaceuticals, Inc. - Common Stock is SNDX on the Nasdaq Stock Market

What is the current price of Syndax Pharmaceuticals, Inc. - Common Stock?

The current price of Syndax Pharmaceuticals, Inc. - Common Stock is 20.16

When was Syndax Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Syndax Pharmaceuticals, Inc. - Common Stock was at 01/20/26 02:05 PM ET

What is the market capitalization of Syndax Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Syndax Pharmaceuticals, Inc. - Common Stock is 1.40B

How many shares of Syndax Pharmaceuticals, Inc. - Common Stock are outstanding?

Syndax Pharmaceuticals, Inc. - Common Stock has 1B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.